Key Highlights
- Loss per share was USD 0.97 against an estimate of a USD 1.02 loss.
- Net loss was USD 51.62 million, compared with USD 29.42 million.
- Research and development expenses were USD 44.21 million, compared with USD 27.09 million.
- Cash, cash equivalents and investments were USD 463.4 million.
MapLight Therapeutics (NASDAQ:MPLT) reported a net loss of USD 51.62 million for the third quarter of 2026, compared with USD 29.42 million in the prior-year quarter. Net loss per share, basic and diluted, was USD 0.97, compared with USD 37.18, against an estimate of a USD 1.02 loss.
For the nine months ended September 30, 2026, the net loss was USD 172.48 million, compared with USD 81.60 million, and net loss per share was USD 3.60, compared with USD 105.70.
Operating Expenses
Research and development expenses were USD 44.21 million, compared with USD 27.09 million, and general and administrative expenses were USD 11.14 million, compared with USD 4.40 million. Total operating expenses and the loss from operations were USD 55.34 million, compared with USD 31.50 million.
Interest income was USD 3.09 million, compared with USD 1.55 million, and other income, net, was USD 633 thousand, compared with USD 531 thousand. Weighted average shares outstanding were 53,100,322.
Nine-Month Results
For the nine months, Research and Development expenses were USD 151.33 million, compared with USD 73.73 million, and general and administrative expenses were USD 32.07 million, compared with USD 11.98 million. Total operating expenses were USD 183.40 million, compared with USD 85.71 million. Interest income was USD 7.92 million, compared with USD 3.05 million.
Cash and Capital Raising
Cash and cash equivalents were USD 55.57 million at September 30, 2026, compared with USD 46.73 million at December 31, 2025, and short-term investments were USD 228.51 million, compared with USD 258.37 million. The filing states that cash, cash equivalents and investments were USD 463.4 million and that, based on current operational plans and assumptions, the company anticipates that these resources are sufficient to fund operations through 2028.
The filing states that in October 2025 the company effected a 1-for-16.8 Reverse Stock Split and closed its initial public offering of 16,962,500 shares at USD 17.00 per share for gross proceeds of USD 288.4 million. In August 2026, the company completed an additional private Placement that generated net proceeds of USD 140.1 million.
The filing states that concurrent with the initial public offering, the company closed a private placement of 476,707 shares of common stock at USD 17.00 per share, with net proceeds of USD 7.5 million, and that the offering itself produced net proceeds of USD 261.6 million. Upon the closing of the offering, outstanding redeemable convertible preferred stock converted into 25,412,974 shares of common stock, of which 2,727,511 shares were non-voting common stock.
The cover of the filing reports 53,480,385 shares of voting common stock and 2,727,511 shares of non-voting common stock outstanding. Prepaid expenses and other current Assets were USD 10.52 million, compared with USD 19.57 million. The filing also references an asset purchase agreement with NeuroSolis, Inc.
MapLight Therapeutics Q3 2026 Earnings: Key Takeaways
MapLight Therapeutics reported a third quarter 2026 net loss of USD 51.62 million and a loss per share of USD 0.97. Cash, cash equivalents and investments were USD 463.4 million at September 30, 2026.






Please wait processing your request...